Search

Now showing items 1-1 of 1

Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials.

George, A; Kristeleit, R; Rafii, S; Michie, CO; Bowen, R; Michalarea, V; van Hagen, T; Wong, M; Rallis, G; Molife, LR; Lopez, J; Banerji, U; Banerjee, SN; Gore, ME; de Bono, JS; Kaye, SB; Yap, TA (2017-05)

Drug resistance to conventional anticancer therapies is almost inevitable in patients with advanced ovarian cancer (AOC), limiting their available treatment options. Novel phase I trial therapies within a dedicated drug ...